Projected retatrutide pricing: $1,000 to $1,500 per month

We estimate retatrutide will fall in the $1,000 to $1,500 per month range at launch. Here is the reasoning.

Retatrutide is a triple agonist (GLP-1, GIP, and glucagon). It is a more complex molecule than tirzepatide, which targets two receptors. More complexity in manufacturing could push costs slightly higher. But Lilly also knows they are competing with Novo Nordisk and will want to maintain their pricing advantage.

If Lilly follows the same playbook, they will price retatrutide competitively against whatever Novo Nordisk charges for CagriSema (their next-generation compound). The exact number will depend on market conditions at launch, but the $1,000 to $1,500 range is the most realistic window based on current data.

Insurance coverage outlook

Insurance coverage for weight loss drugs has been one of the biggest barriers to access. Here is where things stand and where they are heading.

Current reality. Many private insurance plans do not cover GLP-1 medications prescribed specifically for weight loss. Coverage is better when the prescription is for type 2 diabetes. Some employers have added weight loss drug coverage, but it varies widely.

What is changing. Several factors are shifting the landscape in favor of coverage. Medicare coverage for weight loss drugs is under active legislative discussion. The TREAT Act, if passed, would require Medicare to cover FDA-approved anti-obesity medications. Private insurers are also expanding coverage as data shows these drugs reduce long-term healthcare costs.

What this means for retatrutide. Coverage will depend heavily on what indications the FDA approves. If retatrutide receives approval for both obesity and type 2 diabetes, more patients will have a path to coverage. The broader the label, the better the insurance picture.

Eli Lilly savings programs

Lilly has a strong track record with patient savings programs. The Mounjaro savings card was widely used and offered significant discounts for commercially insured patients. Zepbound received a similar program at launch.

We expect Lilly to launch a savings card program for retatrutide as well. These programs typically reduce patient out-of-pocket costs to $25 to $50 per month for eligible patients with commercial insurance. They do not apply to government insurance (Medicare, Medicaid, Tricare).

Lilly also launched LillyDirect, a direct-to-patient platform that offers their medications at lower out-of-pocket costs. Retatrutide will likely be available through this channel.

What about compounded retatrutide?

Compounded semaglutide has been a major story in the weight loss drug market. Compounding pharmacies have offered semaglutide at a fraction of the brand-name price, sometimes $200 to $400 per month versus $1,300 or more.

This happened because the FDA placed semaglutide on its drug shortage list, which allowed compounding pharmacies to legally produce it. That shortage status is now being challenged, and the compounding landscape is shifting.

For retatrutide, compounding is unlikely at launch for several reasons. The drug will be under patent protection. There would be no shortage declaration for a newly launched product. And Lilly will aggressively defend their IP, as they have already done with tirzepatide compounding.

If you see anyone selling "compounded retatrutide" before FDA approval, that product is unregulated and unverified. We recommend avoiding it entirely.

The cost vs. value calculation

Raw monthly cost does not tell the full story. What matters is cost per unit of outcome.

In the Phase 2 trial, retatrutide produced 24.2% body weight loss at the highest dose over 48 weeks. For comparison, Wegovy produced 14.9% in the STEP 1 trial over 68 weeks.

That means retatrutide delivered nearly twice the weight loss in less time. If retatrutide is priced at $1,200 per month and Wegovy at $1,400 per month, the per-pound cost of weight loss with retatrutide would actually be lower.

This matters for patients, but it also matters for insurers. A drug that produces faster, greater weight loss could reduce overall treatment duration and total cost. This economic argument will likely be central to Lilly's pitch for insurance coverage.

For a full breakdown of how these compounds compare head to head, see our comparison guide.

International pricing

Weight loss drug pricing outside the United States is often significantly lower. In many countries, government price negotiations bring costs down to a fraction of US list prices.

Medical tourism for weight loss drugs is growing. Some patients travel to Mexico, Canada, or parts of Europe to access medications at lower costs. This trend will likely continue with retatrutide once it becomes available internationally.

However, we recommend caution. Verify the legitimacy of any international pharmacy. Counterfeit weight loss drugs are a real and growing problem.

Frequently asked questions

How much will retatrutide cost per month?

No official price has been announced. Based on comparable drugs from Eli Lilly, we project $1,000 to $1,500 per month at list price. Patient savings programs could reduce out-of-pocket costs significantly.

Will insurance cover retatrutide?

Coverage will depend on FDA-approved indications and your specific insurance plan. The trend is toward broader coverage of weight loss medications, but nothing is guaranteed for retatrutide yet.

Will there be a generic version of retatrutide?

Not for many years. Retatrutide will be patent-protected at launch. Generic biologics (biosimilars) for complex peptide drugs typically take 10 or more years to reach market after initial approval.

Is retatrutide cheaper than Wegovy?

We do not know yet. But Eli Lilly priced Zepbound 20% below Wegovy at launch, so competitive pricing is likely.

Can I get retatrutide from a compounding pharmacy?

Not legally, and not safely. Retatrutide is not FDA-approved and will be patent-protected. Any product sold as retatrutide outside of clinical trials is unregulated. Learn more about how to get retatrutide through legitimate channels.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. Peptide Nerds shares published research and informed analysis, not medical recommendations.